Due to relatively small samples of individual study and controversial conclusions, we performed this meta-analysis of the literature to analyze whether RASSF1A hypermethylation could readily be harnessed as clinically useful predictive biomarker for breast cancer. Here, RASSF1 is linked to breast cancer.